Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cornulin (CRNN) is a calcium-binding protein predominantly expressed in stratified squamous epithelial tissues such as the skin, esophagus, and cervix[2][4][5]. It belongs to the S100-fused type protein family and is characterized by EF-hand Ca2+ binding domains and repeat-rich C-terminal regions[3][4]. Cornulin is involved in epithelial differentiation and functions as a stress-response protein, potentially acting as a tumor suppressor in squamous cell carcinomas, where its expression is often downregulated during progression[2][5]. However, overexpression of Cornulin in some cancers has cancer-promoting effects by facilitating cell cycle progression and inhibiting apoptosis[1]. It has been shown to regulate epidermal growth, cell cycle G1/S transition (via cyclin D1), and responds to inflammatory or stress signals, with its level serving as a useful biomarker for cancer diagnosis and prognosis in squamous epithelium-derived malignancies[1][2][5]. There are no approved therapeutic drugs that directly target cornulin, and it is not currently considered a direct druggable or therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cornulin (CRNN).